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Background: Postoperative pain management is an imperative issue for patients
undergoing lumbar spinal fusion surgery. Delayed pain relief is associated with poor
clinical outcomes. This study compared the effects of intravenously administered
patient-controlled analgesia (PCA) with intravenous parecoxib, both commonly used
methods for analgesic pain control after surgery.
Methods: A non-randomized study was used to recruit 68 patients who were scheduled
to receive lumbar spinal fusion surgery at a hospital in Taiwan from April through
December of 2020. The group treated with parecoxib received an initial perioperative
dose of parecoxib 40 mg during a 30-min period and then postoperative intravenous
parecoxib at 40 mg per 12-h period, for 72 h. Those with PCA received morphine (0.4
mg/ml), droperidol (0.02 mg/ml), diphenhydramine (0.48 mg/ml), midazolam (0.02 mg/ml)
and saline solution during the 3-day study course. Major outcomes, including visual
scale pain score and Barthel index of activities of daily living, were collected via review
of medical records at 4 times: 12, 24, 48 and 72 h after surgery. Comparative effects
between two groups were assessed by the generalized estimating equations.
Results: After adjusting for potential confounders, the administration of parecoxib was
associated with a significant decrease in pain scores and an increase in the Barthel Index,
when compared with the PCA group (all p < 0.05). Notably, both effects would maintain
for 72 h after surgery.
Discussion: This is the first trial of which the authors are aware, that supports
intravenous parecoxib as significantly enhancing patient mobility, in addition to having
pain control efficacy, when compared with PCA. This study could be used as a reference
when instituting interventions to improve the adaptation process and clinical prognoses
after lumbar spinal fusion surgery.
Keywords: patient-controlled analgesia, parecoxib, lumbar spinal fusion surgery, generalized estimating
equations, pain
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INTRODUCTION

study aimed to clarify the impact of parecoxib, as compared
to PCA, among these patients, using a generalized estimating
equations (GEEs) model.

Pain is a frequent complication following surgery, especially
for those receiving lumbar spinal fusion surgery. A recent
comprehensive study, covering 2,996 cases undergoing
lumbar surgery, reported that low-back pain was the most
frequently reported presenting clinical symptom (73%), followed
by radiculopathy (18%), lower-extremity weakness (8%),
and bowel/bladder symptoms (0.3%) (1). The International
Association for the Study of Pain (IASP) is the leading global
organization supporting the practice of pain and pain relief,
which further defines pain as an “unpleasant sensory and
emotional experience associated with actual or potential tissue
damage” (2). A recent study, however, indicated that nearly
60% of patients experienced inadequate pain control in the
first 24 h after surgery (3). Once the individual undergoing
operation did not experience adequate relief of post-operative
pain, it is expected that the patient may experience delayed
wound recovery and a higher stress response, thereby increasing
length of hospital stay and healthcare costs (4, 5). Therefore,
when managing cases of lumbar spinal fusion surgery, treating
or lessening pain level is strongly indicated and is of high
priority, in addition to following optimal management of all
operating protocols.
Postoperative pain management is one of the most important
issues throughout the perioperative period. Initially, patientcontrolled analgesia (PCA), analgesics that are delivered
immediately, upon patient demand, was utilized due to
insufficient pain relief from conventional intramuscular delivery
of opioids (6, 7). Morphine is the most studied and most
commonly used intravenous drug for PCA. While it is the “first
choice” for PCA, morphine may lead to adverse effects, such
as nausea, vomiting, pruritus, respiratory depression, sedation,
confusion, constipation, and urinary retention (8, 9).
As part of a significant increase in specialized diagnostic and
therapeutic methods, the selective cyclooxygenase-2 (COX-2)
inhibitor, parecoxib sodium (parecoxib), has been more recently
introduced. The parecoxib treatment has been mainly employed
for short-term treatment of postoperative pain, and also used
for the treatment of perioperative analgesia to prevent or
reduce severe postoperative acute pain (10). Currently, it is
being widely utilized in a range of surgical procedures, such
as gastrointestinal surgery (11), prostatectomy (12), gynecologic
laparotomy surgery (6) and liver resection (7).
Based on the findings of studies conducted thus far, the
authors found that reports of the effects of use of parecoxib
on pain reduction were mixed, with several studies showing
significant levels of efficacy, while others reporting no substantial
benefit pain relief (11–13). Significantly, the previous studies
did not adhere to the assumption of independence among
participants’ responses, and did not consider maturation effects
caused by the intrinsic changes over time when evaluating
intervention effects (11–13). These omissions may have led to
premature or inaccurate conclusions. Faced with this gap in
the literature, together with limited information regarding the
head-to-head comparison between PCA and parecoxib among
patients having undergone lumbar spinal fusion surgery, this
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METHODS
Study Design and Participants
An observational, non-randomized study was designed to
evaluate the effects of PCA in comparison with parecoxib
among post-surgery patients at a hospital in Taiwan, from April
through December of 2020. Just as the participants could freely
choose the approach of preemptive analgesia upon their personal
willingness, we utilized the observational, non-randomized
approach to avoid disrupting or altering the pattern of present
care. The inclusion criteria were: (i) being at least 20 years-old at
the time of recruitment; (ii) having no cognitive impairment and
severe complications; (iii) being able to communicate in either
Mandarin or Taiwanese, and (14) having undergone lumbar
spinal fusion surgery (14). To ensure participants’ anonymity, all
questionnaires were marked with an encryption code to facilitate
data analysis, but showed no personal identifiers.

Sample Size Calculation
The sample size needed for this repeated measures research
design was estimated by using Cohen’s methodology (15), where
α was set to 0.05, power to 0.8, and the effect size to 0.16, focusing
on the changes observed across four separate measurements of
pain level in the two groups (16). It was determined, based on
these chosen values, that a sample of at least 56 patients (each
group including 28 patients) was required for data analysis (based
on the G∗ POWER 3.1 analytical software, Franz Faul, Universitat
Kiel, Germany).

Intervention (Treatment)
All enrollees were allowed to choose between receiving either
PCA or 40 mg parecoxib sodium intravenously twice a day for
the following 3 days during the perioperative period. Those
receiving parecoxib were initially given an intravenous bolus of
40 mg parecoxib, a parenteral COX-2-specific inhibitor, during
the perioperation period. The subsequent 40 mg parecoxib was
administered intravenously, at an even, computer-controlled,
rate, every 12 h, throughout a period of 72 h. As to the
participants of PCA group, they received the following
medications: morphine (0.4 mg/ml); droperidol (0.02 mg/ml),
diphenhydramine (0.48 mg/ml), midazolam (0.02 mg/ml) and
saline solution, which was administered with a computerized
intravenous infusion pump for 3 days. The pump intravenously
infused a 3 ml bolus into patients when they pressed a button.
Patients were instructed to press the button when experiencing
postoperative pain. The lock-out time between each bolus
injection was 5 mins. The maximum dose of PCA was limited to
50 ml every 4 h. While receiving the pain relief protocols, patients’
vital signs (heart rate, respiratory rate, blood pressure and oxygen
saturation) were monitored every 5 mins for the first hour and
thereafter every 4 h. Supplemental oxygen by nasal cannula was
provided once the patient’s oxygen saturation fell below 95%.
Besides, rescue analgesia was included in the protocol once the
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and its procedure to all participants. Signed informed consent
was obtained after the patients understood and agreed to share
their information with the research team. Thereafter, the authors
applied an observer-blind approach for data collection. A trained
interviewer, who was not familiar with participants or with the
study design, was assigned to collect all information pertaining
to the outcomes and covariates. All data were obtained at four
time points after surgery, namely at 12, 24, 48, and 72 h. All
participants were followed from the date of enrollment until the
end of the follow-up and were given the option to withdraw from
the study at any time without any penalty.

NRS was above seven, which indicated to severe postoperative
pain and inadequate pain control.

Outcome Assessments
Primary outcome indicators of this study comprised of levels
of pain and mobility, as measured by a self-reported numerical
rating scale (NRS) and the Barthel Index.
The NRS is a subjective measure in which individuals rate
their pain on an eleven-point numerical scale. This scale extends
from 0 (no pain at all) to 10 (worst imaginable pain), where
higher scores are associated with a more severe degree of pain.
The NRS was employed due to its simplicity, reproducibility,
and sensitivity to relatively small changes in pain. A literature
review by Safikhani and colleagues observed that the majority
of published articles recommended the NRS as the most useful
response scale for the assessment of pain in adults (17).
Additionally, based on comparison with the Visual Analogue
Scale (VAS), focusing on pain level as the gold standard, the
NRS was determined to possess good concurrent validity, with
a correlation coefficient of 0.92 (p < 0.001) (18).
Mobility was assessed using the Barthel Index, a widely used
measure of the basic activities of daily living (ADL) (19). The
Barthel Index includes 10 task items and is scored according to
the amount of time or assistance required by the patient. The
10 items are: feeding; bathing; grooming; dressing; continence
of bowels and bladder; transferring to and from a toilet; moving
from wheelchair to bed and return; walking on a level surface
for 45 meters, and; going up and down stairs. The total score
ranges from 0 to 100, with lower scores representing greater
nursing dependency. Lam et al. reported that the Barthel Index
posseses sound predictive validity of clinical outcomes and its
scores have shown good reliability, validity, and responsiveness
among various clinical populations (20). The Barthel Index has
demonstrated high inter-rater reliability (0.95) and test–retest
reliability (0.89), as well as high correlations (0.74–0.8) with other
measures of physical disability (19).

Statistical Analysis
Descriptive and inferential statistical analyses were conducted
in accordance with the study aims. Descriptive parameters,
including means, standard deviations and percentages, were used
to describe the distributions of demographic and disease data.
The baseline differences between the two groups were compared
using t-test and χ2 test as applicable. To evaluate the effect of
treatment on the two groups, across the entire follow-up period,
the generalized estimating equations (GEEs) procedure was
utilized to assess the change pattern of NRS and Barthel Index.
GEEs is a form of regression analysis which extends generalized
linear models into a regression procedure with correlated
observations within subjects. In a GEEs procedure, the standard
errors of estimate are corrected for repeated measurement. In
the present study, the baseline heterogeneity (differences existing
before the intervention) between the experimental and control
groups, and the maturation effects (changes in outcome variables
resulting from the passage of time) were all controlled for by
applying the GEEs method. All analyses were conducted using
SAS statistical software, Version 9.3 together with SPSS 22.0. A
p-value of <0.05 was considered statistically significant.

RESULTS

Covariates

Demographic and Disease Characteristics
of Participants

Additional items addressing patients’ demographic and disease
characteristics were developed according to clinical experience
and literature review, and were gathered by a self-reported
questionnaire. These data included gender, age, educational level,
job status, monthly income and certain lifestyle factors, such
as seeking other alternative treatments to reduce pain, as well
as use of alcohol, recorded as “non-drinker” “current drinker”
or “ex-drinker.” Baseline comorbid health conditions were selfreported and identified by a review of medical records, including
hypertension, diabetes, hepatitis, peptic ulcer, and heart disease.
Usage of analgesic medication prior to surgery was stratified into
two categories, namely, (i) if one ever used relevant medications
for a period of more than 3 months, or (ii) use them for <3
months, e.g., sulindac, celecoxib or tramadol.

A total of 68 patients who had lumbar spinal fusion surgery
were enrolled in the study, with 36 in the PCA group and 32
in the parecoxib group. All 68 patients completed the followup material included in this study. Patients ranged in age from
40 to 76 years, with a mean of 60.6 years. Most patients were
female (67.6%), employed (70.6%), and had low level of alcohol
consumption (88.2%). The majority of patients had a monthly
income of New Taiwan Dollars (NTD) ≤40,000 (52.9%) and
reported having lower level of education (66.2%, defined as
below 9th grade). In terms of disease characteristics, most of the
enrolled patients presented without comorbidities and had ever
been prescribed the anesthetic medications used in this study,
prior to their lumbar spinal fusion surgery (86.8%). The mean
duration of pain experience prior to surgery was 2.93 years.

Data Collection Procedure

Baseline Comparison of Demographic and
Disease Characteristics Between Groups

The study protocol was approved by the Research Ethics
Committee of Dalin Tzu Chi Hospital (No. B10901022-1). At
the study’s initiation, researchers explained the purpose of study
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Following univariate analysis to determine baseline differences,
it was observed that the demographic data for subjects in
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TABLE 1 | Demographic and clinical characteristics of study participants by group.
Variables

All participants (N = 68)

PCA (n = 36)

Parecoxib (n = 32)

N

%

N

%

N

%

Male

22

32.4

12

33.3

10

31.3

Female

46

67.6

24

66.7

22

68.7

Low (≤40,000)

36

52.9

18

50.0

18

56.2

High (>40,000)

32

47.1

18

50.0

14

43.8

No

60

88.2

29

80.6

31

96.9

Ever use

8

11.8

7

19.4

1

3.1

Low (≤9 years)

45

66.2

25

69.4

20

62.5

High (>9 years)

23

33.8

11

30.6

12

37.5

48

70.6

28

77.8

20

62.5

P

Demographic data
Sex

0.86

Monthly income

0.61

Alcohol

0.11

Education

0.55

Job
Employed
Unemployed

0.17
20

29.4

8

22.2

12

37.5

60.66

7.86

59.86

7.66

61.56

8.01

No

41

60.3

23

63.9

18

56.2

Yes

27

39.7

13

36.1

14

43.8

No

55

80.9

29

80.6

26

81.3

Yes

13

19.1

7

19.4

6

18.7

No

63

92.6

33

91.7

30

93.7

Yes

5

7.4

3

8.3

2

6.3

No

62

91.2

31

86.1

31

96.9

Yes

6

8.8

5

13.9

1

3.1

No

65

95.6

33

91.7

32

100.0

Yes

3

4.4

3

8.3

0

0

9

13.2

5

13.9

4

12.5
87.5

Age (years) (mean ± SD)

0.38

Clinical characteristics
Hypertension

0.52

Diabetes

0.94

Hepatitis

0.74

Peptic ulcer disease

0.12

Heart diseases

0.10

Ever use of analgesics before surgery
No
Yes

0.87
59

86.8

31

86.1

28

Initial NRS (mean ± SD)

5.91

1.49

5.06

1.16

6.67

1.35

<0.01

Initial Barthel Index (mean ± SD)

33.7

7.95

37.7

8.42

30.1

5.54

<0.01

Disease duration of pain (mean ± SD)

2.93

4.33

3.14

4.74

2.69

3.87

0.70

Primary Outcomes Between the Two
Groups

the PCA group were mostly comparable to those in the
parecoxib group. However, several statistically significant
differences in relation to baseline disease characteristics
between them were found. Subjects in the parecoxib group
were significantly more likely to experience pre-intervention
higher levels of NRS scores and lower Barthel Index score
than those receiving PCA treatment (both p < 0.01)
(Table 1).
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Table 2 displays the GEEs results of NRS scores for the two
groups. A notable difference was demonstrated for baseline NRS
scores between them. Additionally, the NRS scores at T2 and
T3 were statistically different from those at T0, implying a
maturation effect may occur. After adjusting for the maturation
effect together with baseline heterogeneity by GEEs model, the
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TABLE 2 | GEEs model of the NRS scores among subjects (n = 68).
Variable

Regression coefficient

Standard error

P

Intercept

5.06

0.36

<0.01

Group 1 (parecoxib)
vs. Group 0 (PCA)

1.61

0.33

<0.01

T1 vs. T0

−1.16

0.13

<0.01

T2 vs. T0

−1.47

0.15

<0.01

T3 vs. T0

−2.13

0.17

<0.01

Interaction of T1
and group

−0.18

0.22

0.41

Interaction of T2
and group

−0.58

0.28

0.09

Interaction of T3
and group

−0.94

0.34

<0.01

FIGURE 2 | Barthel index of patients in the parecoxib and PCA. T0, at 12 h
after surgery; T1, at 24 h after surgery; T2, at 48 h after surgery, and T3, at
72 h after surgery.

(p < 0.01) (Table 3). After controlling for baseline differences
and maturation effect, the increased level of Barthel Index in the
parecoxib group was significantly higher than that in PCA group
at both T2 and T3, with β values of 4.36 and 6.26 (all p values <
0.05; Figure 2), respectively.

DISCUSSION
For those with degenerative lumbar disease, lumbar spinal fusion
surgery has become an increasingly common therapeutic option.
A persistent challenge in a significant number of cases has been
postoperative pain, leading to delay of early ambulation after
surgery, thereby resulting in delayed recovery and increased
risk of mortality (4, 5). Currently, various preemptive analgesic
strategies have been developed to address the postoperative
pain issue, such as treatment with PCA or parecoxib. However,
the studies designed to directly compare the effects of these
two methods have been somewhat limited and sometimes
controversial (11–13). Most importantly, previous researchers,
periodically, neglected to account for specific baseline differences
between groups and for autocorrelation among subjects across
time, which could have prejudiced conclusions. The present
study is possibly the first study to compare the impacts on
pain and daily activities by PCA and parecoxib using the
GEEs model.
After adjusting for baseline differences between the two
groups and for maturation effects, as determined by the GEEs
model, it was observed that the perioperative administration of
parecoxib was related to a higher level of postoperative daily
activities, when compared to the PCA group. However, since
no previous studies have been conducted comparing the impact
of PCA and parecoxib, on daily activities no direct comparison
of results is therefore possible. Notwithstanding, the positive
effect of parecoxib use on physical activity observed in this
study was consistent with findings of earlier reports, and adds
to the growing body of literature on this topic (10, 21). It
is well known that morphine, or other opioids, is the most
widely used intravenous drug for PCA, even as these common
medications may be related to several adverse effects, such as
nausea, vomiting, respiratory depression, sedation, constipation,
confusion and urinary retention (8, 9). Taken the lung function as

FIGURE 1 | NRS score of patients in the parecoxib and PCA. T0, at 12 h after
surgery; T1, at 24 h after surgery; T2, at 48 h after surgery, and T3, at 72 h
after surgery.

TABLE 3 | GEEs model of the Barthel index scores among subjects (n = 68).
Variable

Regression coefficient

Standard error

P

Intercept

33.82

2.49

<0.01

Group 1 (parecoxib)
vs. Group 0 (PCA)

−8.85

2.04

<0.01

T1 vs. T0

25.94

1.49

<0.01

T2 vs. T0

40.78

1.48

<0.01

T3 vs. T0

47.91

1.50

<0.01

Interaction of T1
and group

0.04

2.62

0.99

Interaction of T2
and group

4.36

2.07

0.04

Interaction of T3
and group

6.26

1.93

<0.01

reduction slope of NRS score was evident for the parecoxib group
compared with the PCA group, particularly in the third time
measurement that reached statistically significance (p < 0.01;
Figure 1). In addition, no rescue analgesia was required during
the perioperative period.
Regarding the mobility change scores between the two groups,
the analysis revealed that the Barthel Index score increased with
time, which supported the occurrence of a maturation effect
(p < 0.01). The subjects in the parecoxib group reported lower
Barthel Index scores than those in the PCA group at baseline

Frontiers in Surgery | www.frontiersin.org
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type I error to some extent (28). Finally, the future prospective
randomized trials upon the larger sample size are needed to
overcome the limitations of this study to provide more definite
evidence of the findings reported.

a example, it was found to be inversely associated with functional
limitation. An earlier study showed that ∼40% of patients with
chronic lung diseases were prone to suffer some degree of
disability and 68% lost at least one relevant function of daily
living (22). Gao and colleagues also reported that those with poor
lung function, as assessed by the FVC < 0.76 criterion, would be
at nearly twice the risk of developing functional limitation (23).
In the present study, those receiving parecoxib had a
significantly greater reduction in pain score than those receiving
PCA after adjusting for the baseline heterogeneity along with
inherent mature effect, and this beneficial effect was maintained
for 72 h after undergoing surgery, echoing the earlier study
finding (24). Several studies found that by suppressing the
production of the pro-inflammatory cytokines containing TNFalpha and IL-1beta, the COX-2 selective inhibitors were found
to offer a number of advantages over classical non-steroidal
anti-in?ammatory drugs, when used to treat postoperative pain
(25, 26). These included an elimination of inhibitory effect on
platelet function, thereby reducing the risk of blood loss. In
addition, the use of COX-2 inhibitors less inflected impairment
of bone healing (27), which may explain why the use of parecoxib
could relieve pain to exhibit an opioid-sparing effect following
lumbar spine fusion surgery.
In a head-to-head comparison of the effects of parecoxib and
PCA, regarding pain and daily activities, the GEEs model was
used to adjust for baseline differences and temporal maturation
effect, allowing for a more robust determination of the study
findings. Several limitations, however, should be noted when
interpreting the results. First, all participants were drawn from
a single hospital in southern Taiwan, so inferences drawn from
the results may not be generalizable to populations in other
geographic regions. However, prior to the implementation of the
study, the sample size required to ensure statistical power was
calculated and the sample size used in this study may, therefore,
be considered satisfactory for the data analysis undertaken.
Previous studies also faced barriers to their generalizability,
because of participants’ restricted ethnicity, geographic location,
nationality, and the nature of the medical data available,
suggesting that this limitation is not unique to our study. Second,
the application of an observational non-randomized study may
have weakened the internal validity of the research. This is
because the current study was not randomized and there may
have been disparities between two groups in the surgerical
procedures that were not measured to possibly affect the findings
herein. Nevertheless, in this investigation, we employed the
GEEs model to control for baseline differences between the two
groups, and further considered the potential maturation effects;
this approach differed from the priori conventional repeated
measures and would likely reduce the probability of inflated

CONCLUSION
As far as the authors are aware, this is the first study to
directly compare the different effects on pain and activities
of daily living of the infusion of parecoxib and PCA, from
a longitudinal perspective. After using the repeated measure
of GEEs methodology, the results demonstrated that use of
an intravenous infusion pump for parecoxib provided superior
analgesic efficacy after lumbar spinal fusion surgery, when
compared to PCA. As compared to use of PCA, using the
parecoxib pump remarkably reduced the NRS scores throughout
the 72-h study period, and patients who receive this treatment
also reported higher levels of physical activity. This research
provides evidence of the positive effects of Parecoxib use among
those with lumbar spinal fusion surgery, particularly in terms of
reducing postsurgical pain and facilitating movement.
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